0444631 - BTÚ 2016 RIV NL eng J - Journal Article
Koudelka, S. - Knotigova, P.T. - Masek, J. - Prochazka, L. - Lukac, R. - Miller, A.D. - Neužil, Jiří - Turanek, J.
Liposomal delivery systems for anti-cancer analogues of vitamin E.
Journal of Controlled Release. Roč. 207, Jun 10 (2015), s. 59-69. ISSN 0168-3659. E-ISSN 1873-4995
R&D Projects: GA MŠMT(CZ) ED1.1.00/02.0109
Institutional support: RVO:86652036
Keywords : Alpha-tocopheryl succinate * Analogues of vitamin E * Anti-cancer drugs
Subject RIV: EB - Genetics ; Molecular Biology
Impact factor: 7.441, year: 2015
DOI: https://doi.org/10.1016/j.jconrel.2015.04.003

Pro-apoptotic analogues of vitamin E (VE) exert selective anti-cancer effect on various animal cancer models. Neither suitable formulation of a-tocopheryl succinate (alpha-TOS), representative semi-synthetic VE analogue ester, nor suitable formulations of the other VE analogues for clinical application have been reported yet. The major factor limiting the use of VE analogues is their low solubility in aqueous solvents. Due to the hydrophobic character of VE analogues, liposomes are predetermined as suitable delivery system. Liposomal formulation prevents undesirable side effects of the drug, enhances the drug biocompatibility, and improves the drug therapeutic index. Liposomal formulations of VE analogues especially of alpha-TOS and alpha-tocopheryl ether linked acetic acid (alpha-TEA) have been developed. The anti-cancer effect of these liposomal VE analogues has been successfully demonstrated in pre-clinical models in vivo. Present achievements in: (i) preparation of liposomal formulations of VE analogues, (ii) physico-chemical characterization of these developed systems and (iii) testing of their biological activity such as induction of apoptosis and evaluation of anti-cancer effect are discussed in this review. (C) 2015 Elsevier B.V. All rights reserved.

Permanent Link: http://hdl.handle.net/11104/0247114